Key Takeaways International expansion and partnerships are driving greater market access, positioning the company for sustained revenue growth in advanced respiratory care. Product innovation and operational efficiencies are improving scalability, margin potential, and revenue stability through recurring contracts and long-term customer relationships.Read more
Key Takeaways Accelerating hospital access and international partnerships could significantly outpace current revenue expectations, fueling rapid global growth opportunities. Recurring revenue from consumables and unique technology positions Beyond Air for strong earnings growth and strategic advantage in a transforming healthcare market.Read more
Key Takeaways Slow onboarding in hospitals and regulatory hurdles may significantly restrict revenue growth and the ability to capitalize on expanding market access. Heavy reliance on a single core product and growing competition from advanced medtech firms increase both revenue concentration risk and margin pressure.Read more
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
